These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15462254)

  • 1. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions.
    Motl S; Timpe E; Eichner S
    Am J Health Syst Pharm; 2004 Sep; 61(17):1840-2. PubMed ID: 15462254
    [No Abstract]   [Full Text] [Related]  

  • 2. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA announces MedWatch: a new reporting program for health professionals.
    Hopkinson SE
    AANA J; 1993 Aug; 61(4):373-8. PubMed ID: 8379285
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 5. Panel backs pain drug studies with new safety checks.
    Dolgin E
    Nat Med; 2012 Apr; 18(4):472. PubMed ID: 22481387
    [No Abstract]   [Full Text] [Related]  

  • 6. New vaccine reports from FDA to the Uppsala Monitoring Centre.
    Hill R
    Int J Risk Saf Med; 2011; 23(2):117-8. PubMed ID: 21673420
    [No Abstract]   [Full Text] [Related]  

  • 7. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 9. Making all clinical trials available for review: any impact on clinical decisions?
    Smith GH
    J Am Pharm Assoc (2003); 2005; 45(1):7-8. PubMed ID: 15730109
    [No Abstract]   [Full Text] [Related]  

  • 10. Reporting of adverse events to MedWatch.
    Piazza-Hepp TD; Kennedy DL
    Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food and Drug Administration update. The MedWatch program.
    White GG; Love L
    J Toxicol Clin Toxicol; 1998; 36(1-2):145-9. PubMed ID: 9541064
    [No Abstract]   [Full Text] [Related]  

  • 12. Reporting of adverse drug reactions by poison control centres in the US.
    Chyka PA; McCommon SW
    Drug Saf; 2000 Jul; 23(1):87-93. PubMed ID: 10915034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA drug safety surveillance program: adverse event reporting trends.
    Weiss-Smith S; Deshpande G; Chung S; Gogolak V
    Arch Intern Med; 2011 Mar; 171(6):591-3. PubMed ID: 21444854
    [No Abstract]   [Full Text] [Related]  

  • 15. MedWatch targets reporting of serious adverse events.
    VanAmringe M
    Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
    [No Abstract]   [Full Text] [Related]  

  • 16. Experts call for active surveillance of drug safety.
    Wadman M
    Nature; 2007 Mar; 446(7134):358-9. PubMed ID: 17377551
    [No Abstract]   [Full Text] [Related]  

  • 17. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch.
    Smith KM; Lawson AP; Tuteja S
    Am J Health Syst Pharm; 2006 May; 63(10):949-52. PubMed ID: 16675652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.